Filtered By:
Condition: Dermatitis
Cancer: Squamous Cell Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 106 results found since Jan 2013.
Monitoring Adverse Effects of Radiation Therapy in Patients With Head and Neck Cancer: The FACT-HN-RAD Patient-Reported Outcome Measure
CONCLUSIONS AND RELEVANCE: The 8-item FACT-HN-RAD measure captures the most common patient- and physician-reported AEs related to RT for HNSCC. This measure offers a means to serially monitor patient-reported treatment-related AEs and recovery over time in both clinical and research settings. Future work will evaluate the psychometric validity of the measure.PMID:37589994 | DOI:10.1001/jamaoto.2023.2177
Source: Pain Physician - August 17, 2023 Category: Anesthesiology Authors: Laila A Gharzai Michelle L Mierzwa John Devin Peipert Kedar Kirtane Keith Casper Poonam Yadav Nan Rothrock David Cella Sara Shaunfield Source Type: research
Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial
CONCLUSIONS: These results suggest that eliminating ENI is oncologically sound for HNSCC, with highly favorable quality-of-life outcomes. Additional prospective studies are needed to support this promising paradigm before implementation in any non-trial setting.PMID:37363993 | DOI:10.1158/1078-0432.CCR-23-0334
Source: Clinical Cancer Research - June 26, 2023 Category: Cancer & Oncology Authors: David J Sher Dominic H Moon Dat Vo Jing Wang Liyuan Chen Michael Dohopolski Randall Hughes Baran D Sumer Chul Ahn Vladimir Avkshtol Source Type: research
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial
CONCLUSION: Panitumumab in combination with CRT for locally advanced SCCA failed to meet the expected CR rate and exhibited a poor tolerance. Furthermore, late RFS, CFS, and OS did not suggest any outcome improvement to justify further clinical trials.PMID:37315583 | DOI:10.1016/j.radonc.2023.109742
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - June 14, 2023 Category: Radiology Authors: V éronique Vendrely Philippe Ronchin Mathieu Minsat Karine Le Malicot Claire Lemanski Xavier Mirabel Pierre-Luc Etienne Astrid Li èvre Ariane Darut-Jouve Christelle de la Fouchardi ère Nicolas Giraud Gilles Breysacher Delphine Argo-Leignel Elsa Thimonn Source Type: research
Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903)
CONCLUSIONS: Although the primary endpoint was not met, S-1/mitomycin-C chemoradiotherapy had an acceptable toxicity profile and favorable 3-year survival and could be a treatment option for locally advanced SCCA.CLINICAL TRIAL INFORMATION: jRCTs031180002.PMID:37286878 | DOI:10.1007/s10147-023-02361-7
Source: Clinical Colorectal Cancer - June 7, 2023 Category: Cancer & Oncology Authors: Yoshinori Ito Tetsuya Hamaguchi Atsuo Takashima Junki Mizusawa Yasuhiro Shimada Manabu Shiozawa Nobutaka Mizoguchi Takeshi Kodaira Koji Komori Masayuki Ohue Koji Konishi Fuminori Teraishi Makoto Kinouchi Kohei Murata Fumihiko Fujita Masahiko Watanabe Gen Source Type: research
Hypofractionated radiotherapy for invasive squamous cell carcinoma of the scalp in the elderly: Efficacy and tolerance, preliminary results
CONCLUSION: Short term of moderately hypofractionated schedule radiotherapy was a success with complete or partial response for more than 70% of the patients in squamous cell carcinomas. There is no major side effect.PMID:37179219 | DOI:10.1016/j.canrad.2023.01.003
Source: Cancer Radiotherapie - May 13, 2023 Category: Cancer & Oncology Authors: J Jacques S Renard N Demogeot J C Faivre D Peiffert Source Type: research
